CERo Therapeutics Holdings, Inc. (CERO)
OTCMKTS
· Delayed Price · Currency is USD
0.107
-0.006 (-5.56%)
At close: Dec 5, 2025
CERo Therapeutics Holdings Employees
CERo Therapeutics Holdings had 8 employees as of December 31, 2024. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$6,148,877
Market Cap
2.38M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8 | -1 | -11.11% |
| Dec 31, 2023 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Elite Pharmaceuticals | 68 |
| Glass House Brands | 374 |
| CytoDyn | 13 |
| American Oncology Network | 1,914 |
| Northwest Biotherapeutics | 25 |
| Silence Therapeutics | 116 |
| Zomedica | 152 |
CERo Therapeutics Holdings News
- 3 days ago - CERo Therapeutics Announces Trading on OTCQB Market - GlobeNewsWire
- 4 weeks ago - CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing - GlobeNewsWire
- 4 weeks ago - CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response - GlobeNewsWire
- 5 weeks ago - CERo Therapeutics Announces Receipt of Nasdaq Panel Determination - GlobeNewsWire
- 6 weeks ago - CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML - GlobeNewsWire
- 7 weeks ago - CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025 - GlobeNewsWire
- 7 weeks ago - CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML - GlobeNewsWire
- 2 months ago - CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort - GlobeNewsWire